Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Exploring ‘Compassionate Use’

A two-day conference brought together representatives from government, pharmaceutical companies, patient groups, NGOs, and foundations, to discuss how to manage pre-approval access to medicines.

Published December 08, 2015

"Imagine that someone you love was a matter of days from succumbing to a fatal infection, but the drug of last resort-and your only hope - had not yet emerged from the trials and approvals needed to reach the marketplace," said Fred Guterl, BSEE, Executive Editor, Scientific American. How can our society, including patients, physicians, pharmaceutical companies, and government regulators, handle such cases in way that is compassionate, effective, and safe?

Such was the discussion on October 28 - 29 at the conference eBriefing, a multimedia conference report, as well as a Podcast, in mid-January.